Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1992-11

AUTHORS

Howard Bailey, Peter Kohler, Richard Tuttle, Paul P. Carbone, John A. Hohneker, Neil J. Clendeninn, George Wilding

ABSTRACT

One of a novel series of compounds (AMAPS or arylmethylaminopropanediols), 773U82-HCl has shown significant antitumor activity in in vitro and in in vivo tumor systems, but has less animal CNS toxicity than the lead compound in the same series (crisnatol). This study was designed to evaluate the pharmacokinetics, qualitative and quantitative toxicities of 773U82-HCl and to determine the recommended phase II dose (MTD) of 773U82-HCl given as a short infusion daily for 3 days every 3 weeks. Twenty-nine patients with refractory malignancies received 79 courses over 9 dose levels during this study. Doses ranged from 50 to 1060 mg/m2/d x 3 days. Due to the possibility of local hemolysis with concentrations > 1.5 mg/ml, drug was administered in solutions containing < or = 1.5 mg/ml. Because large volumes were needed at the higher dose levels, the infusion duration was increased from 2 hours to 4 hours. Mild to moderate nausea, vomiting, fatigue, dizziness and headaches were observed. Myelosuppression was the dose limiting toxicity. The recommended phase II dose and schedule was determined to be 800 mg/m2/d x 3d every 3 weeks. 773U82-HCl plasma concentration-time data were analyzed using a two-compartment pharmacokinetic model. The t1/2 beta averaged 6 hours and the total body clearance was 75.9 L/hr/m2. The volume of distribution (Vdss) was large, averaging 470 L/m2. More... »

PAGES

279-287

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00944182

DOI

http://dx.doi.org/10.1007/bf00944182

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035833170

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1487401


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorenes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Propylene Glycols", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "UW Carbone Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.412639.b", 
          "name": [
            "University of Wisconsin Clinical Cancer Center, 53792, Madison, Wisconsin, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bailey", 
        "givenName": "Howard", 
        "id": "sg:person.010415604757.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010415604757.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Meriter-Madison General Hospital, 53715, Madison, Wisconsin, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kohler", 
        "givenName": "Peter", 
        "id": "sg:person.01224222702.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224222702.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Burroughs Wellcome Co., 27709, Research Triangle Park, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tuttle", 
        "givenName": "Richard", 
        "id": "sg:person.0716677131.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716677131.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UW Carbone Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.412639.b", 
          "name": [
            "University of Wisconsin Clinical Cancer Center, 53792, Madison, Wisconsin, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carbone", 
        "givenName": "Paul P.", 
        "id": "sg:person.01047163115.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047163115.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Burroughs Wellcome Co., 27709, Research Triangle Park, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hohneker", 
        "givenName": "John A.", 
        "id": "sg:person.0762066407.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762066407.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Burroughs Wellcome Co., 27709, Research Triangle Park, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clendeninn", 
        "givenName": "Neil J.", 
        "id": "sg:person.01341116525.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341116525.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "William S. Middleton Memorial Veterans Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417123.2", 
          "name": [
            "University of Wisconsin Clinical Cancer Center, 53792, Madison, Wisconsin, USA", 
            "William S. Middleton Memorial Veterans Administration Hospital, 53705, Madison, Wisconsin, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilding", 
        "givenName": "George", 
        "id": "sg:person.016113722177.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016113722177.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00194543", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041178803", 
          "https://doi.org/10.1007/bf00194543"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-199108000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044752701"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-199108000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044752701"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078552732", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079722375", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1992-11", 
    "datePublishedReg": "1992-11-01", 
    "description": "One of a novel series of compounds (AMAPS or arylmethylaminopropanediols), 773U82-HCl has shown significant antitumor activity in in vitro and in in vivo tumor systems, but has less animal CNS toxicity than the lead compound in the same series (crisnatol). This study was designed to evaluate the pharmacokinetics, qualitative and quantitative toxicities of 773U82-HCl and to determine the recommended phase II dose (MTD) of 773U82-HCl given as a short infusion daily for 3 days every 3 weeks. Twenty-nine patients with refractory malignancies received 79 courses over 9 dose levels during this study. Doses ranged from 50 to 1060 mg/m2/d x 3 days. Due to the possibility of local hemolysis with concentrations > 1.5 mg/ml, drug was administered in solutions containing < or = 1.5 mg/ml. Because large volumes were needed at the higher dose levels, the infusion duration was increased from 2 hours to 4 hours. Mild to moderate nausea, vomiting, fatigue, dizziness and headaches were observed. Myelosuppression was the dose limiting toxicity. The recommended phase II dose and schedule was determined to be 800 mg/m2/d x 3d every 3 weeks. 773U82-HCl plasma concentration-time data were analyzed using a two-compartment pharmacokinetic model. The t1/2 beta averaged 6 hours and the total body clearance was 75.9 L/hr/m2. The volume of distribution (Vdss) was large, averaging 470 L/m2.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00944182", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2682633", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "name": "Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days", 
    "pagination": "279-287", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "aab25800976c5c990de5c7339101adef0bb9241a1729ded6ab91fe2a188b8607"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1487401"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00944182"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035833170"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00944182", 
      "https://app.dimensions.ai/details/publication/pub.1035833170"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000370_0000000370/records_46777_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00944182"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00944182'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00944182'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00944182'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00944182'


 

This table displays all metadata directly associated to this object as RDF triples.

184 TRIPLES      21 PREDICATES      45 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00944182 schema:about N2cf47b9560a9462dbcb93b71fc2138b7
2 N36df6aa84b5945c68e4da4ec63b9db19
3 N5c9911ed1079432db4e9a0d4f348b1f6
4 N84c58fc4441a4527b586f58aa8860f3e
5 N93cfdba38cef4931a8dcad74e6c8a8e8
6 N97168f92dc034ffe9ebb1939270f9652
7 Nb0eb75471be649169fffd54f8ef3c672
8 Nb4419b57547f4ccab4f8202a2e0bf5d8
9 Nbd55a52ab92e485e9744f148638b7fa0
10 Nbe893817aa214c5fa6bf6b7e35706bd0
11 Nc030d61eb61b4266b900e9958b1cd7da
12 Nd101c075af98403f830598178096bb41
13 anzsrc-for:11
14 anzsrc-for:1115
15 schema:author N659733e1749a46e2a254dff65337b37e
16 schema:citation sg:pub.10.1007/bf00194543
17 https://app.dimensions.ai/details/publication/pub.1078552732
18 https://app.dimensions.ai/details/publication/pub.1079722375
19 https://doi.org/10.1097/00001813-199108000-00004
20 schema:datePublished 1992-11
21 schema:datePublishedReg 1992-11-01
22 schema:description One of a novel series of compounds (AMAPS or arylmethylaminopropanediols), 773U82-HCl has shown significant antitumor activity in in vitro and in in vivo tumor systems, but has less animal CNS toxicity than the lead compound in the same series (crisnatol). This study was designed to evaluate the pharmacokinetics, qualitative and quantitative toxicities of 773U82-HCl and to determine the recommended phase II dose (MTD) of 773U82-HCl given as a short infusion daily for 3 days every 3 weeks. Twenty-nine patients with refractory malignancies received 79 courses over 9 dose levels during this study. Doses ranged from 50 to 1060 mg/m2/d x 3 days. Due to the possibility of local hemolysis with concentrations > 1.5 mg/ml, drug was administered in solutions containing < or = 1.5 mg/ml. Because large volumes were needed at the higher dose levels, the infusion duration was increased from 2 hours to 4 hours. Mild to moderate nausea, vomiting, fatigue, dizziness and headaches were observed. Myelosuppression was the dose limiting toxicity. The recommended phase II dose and schedule was determined to be 800 mg/m2/d x 3d every 3 weeks. 773U82-HCl plasma concentration-time data were analyzed using a two-compartment pharmacokinetic model. The t1/2 beta averaged 6 hours and the total body clearance was 75.9 L/hr/m2. The volume of distribution (Vdss) was large, averaging 470 L/m2.
23 schema:genre research_article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf Na5a5d13dcc804476933c728156dfc423
27 Na9704d741168431d9596283631bab435
28 sg:journal.1094201
29 schema:name Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days
30 schema:pagination 279-287
31 schema:productId N0645be47584d4008ab0a36900a1cd3bc
32 N2001c370d5d244b0b99600e79ab633f0
33 N7486e7b100bd4da58b3b9535b2cdc89e
34 Nc7a125b67af94d35a1edf0fa7954124a
35 Ndd7afdfa2aa141d1a728a209a1f6320b
36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035833170
37 https://doi.org/10.1007/bf00944182
38 schema:sdDatePublished 2019-04-11T13:36
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher Na2b39b05e07b4159b790bd494146a331
41 schema:url http://link.springer.com/10.1007/BF00944182
42 sgo:license sg:explorer/license/
43 sgo:sdDataset articles
44 rdf:type schema:ScholarlyArticle
45 N0645be47584d4008ab0a36900a1cd3bc schema:name nlm_unique_id
46 schema:value 8309330
47 rdf:type schema:PropertyValue
48 N080c28d5a0094e2fbdd025bb6b4e1517 rdf:first sg:person.01047163115.56
49 rdf:rest N99586024e417488a845fca9e3d1dd1f4
50 N0d04df924cd84c928e49a6dd094697d0 rdf:first sg:person.0716677131.78
51 rdf:rest N080c28d5a0094e2fbdd025bb6b4e1517
52 N2001c370d5d244b0b99600e79ab633f0 schema:name pubmed_id
53 schema:value 1487401
54 rdf:type schema:PropertyValue
55 N2cf47b9560a9462dbcb93b71fc2138b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
56 schema:name Male
57 rdf:type schema:DefinedTerm
58 N36df6aa84b5945c68e4da4ec63b9db19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Infusions, Intravenous
60 rdf:type schema:DefinedTerm
61 N427aeb9845074c6d870d4005175b55d1 rdf:first sg:person.01341116525.73
62 rdf:rest N8e472eb1cf2942aca1ff85f37b39b422
63 N506397512d4b4679991c128f27a561fd schema:name Burroughs Wellcome Co., 27709, Research Triangle Park, North Carolina, USA
64 rdf:type schema:Organization
65 N5c9911ed1079432db4e9a0d4f348b1f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Antineoplastic Agents
67 rdf:type schema:DefinedTerm
68 N659733e1749a46e2a254dff65337b37e rdf:first sg:person.010415604757.37
69 rdf:rest Nce7d128c3291494a902c0193209090ed
70 N6c792b592f8b4c3a9f91c02228903e75 schema:name Burroughs Wellcome Co., 27709, Research Triangle Park, North Carolina, USA
71 rdf:type schema:Organization
72 N7486e7b100bd4da58b3b9535b2cdc89e schema:name dimensions_id
73 schema:value pub.1035833170
74 rdf:type schema:PropertyValue
75 N84c58fc4441a4527b586f58aa8860f3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Aged
77 rdf:type schema:DefinedTerm
78 N8e472eb1cf2942aca1ff85f37b39b422 rdf:first sg:person.016113722177.62
79 rdf:rest rdf:nil
80 N93cfdba38cef4931a8dcad74e6c8a8e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Drug Administration Schedule
82 rdf:type schema:DefinedTerm
83 N97168f92dc034ffe9ebb1939270f9652 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Female
85 rdf:type schema:DefinedTerm
86 N99586024e417488a845fca9e3d1dd1f4 rdf:first sg:person.0762066407.91
87 rdf:rest N427aeb9845074c6d870d4005175b55d1
88 Na2b39b05e07b4159b790bd494146a331 schema:name Springer Nature - SN SciGraph project
89 rdf:type schema:Organization
90 Na5a5d13dcc804476933c728156dfc423 schema:volumeNumber 10
91 rdf:type schema:PublicationVolume
92 Na9704d741168431d9596283631bab435 schema:issueNumber 4
93 rdf:type schema:PublicationIssue
94 Nb0eb75471be649169fffd54f8ef3c672 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Propylene Glycols
96 rdf:type schema:DefinedTerm
97 Nb4419b57547f4ccab4f8202a2e0bf5d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Middle Aged
99 rdf:type schema:DefinedTerm
100 Nbd55a52ab92e485e9744f148638b7fa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Fluorenes
102 rdf:type schema:DefinedTerm
103 Nbe893817aa214c5fa6bf6b7e35706bd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Neoplasms
105 rdf:type schema:DefinedTerm
106 Nc01510045780417fbec4cc12cda582d5 schema:name Burroughs Wellcome Co., 27709, Research Triangle Park, North Carolina, USA
107 rdf:type schema:Organization
108 Nc030d61eb61b4266b900e9958b1cd7da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Adult
110 rdf:type schema:DefinedTerm
111 Nc7a125b67af94d35a1edf0fa7954124a schema:name readcube_id
112 schema:value aab25800976c5c990de5c7339101adef0bb9241a1729ded6ab91fe2a188b8607
113 rdf:type schema:PropertyValue
114 Nce7d128c3291494a902c0193209090ed rdf:first sg:person.01224222702.25
115 rdf:rest N0d04df924cd84c928e49a6dd094697d0
116 Nd101c075af98403f830598178096bb41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 Nd2e7cd1a3c6d46329853d64ef656b92f schema:name Meriter-Madison General Hospital, 53715, Madison, Wisconsin, USA
120 rdf:type schema:Organization
121 Ndd7afdfa2aa141d1a728a209a1f6320b schema:name doi
122 schema:value 10.1007/bf00944182
123 rdf:type schema:PropertyValue
124 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
125 schema:name Medical and Health Sciences
126 rdf:type schema:DefinedTerm
127 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
128 schema:name Pharmacology and Pharmaceutical Sciences
129 rdf:type schema:DefinedTerm
130 sg:grant.2682633 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00944182
131 rdf:type schema:MonetaryGrant
132 sg:journal.1094201 schema:issn 0167-6997
133 1573-0646
134 schema:name Investigational New Drugs
135 rdf:type schema:Periodical
136 sg:person.010415604757.37 schema:affiliation https://www.grid.ac/institutes/grid.412639.b
137 schema:familyName Bailey
138 schema:givenName Howard
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010415604757.37
140 rdf:type schema:Person
141 sg:person.01047163115.56 schema:affiliation https://www.grid.ac/institutes/grid.412639.b
142 schema:familyName Carbone
143 schema:givenName Paul P.
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047163115.56
145 rdf:type schema:Person
146 sg:person.01224222702.25 schema:affiliation Nd2e7cd1a3c6d46329853d64ef656b92f
147 schema:familyName Kohler
148 schema:givenName Peter
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224222702.25
150 rdf:type schema:Person
151 sg:person.01341116525.73 schema:affiliation Nc01510045780417fbec4cc12cda582d5
152 schema:familyName Clendeninn
153 schema:givenName Neil J.
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341116525.73
155 rdf:type schema:Person
156 sg:person.016113722177.62 schema:affiliation https://www.grid.ac/institutes/grid.417123.2
157 schema:familyName Wilding
158 schema:givenName George
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016113722177.62
160 rdf:type schema:Person
161 sg:person.0716677131.78 schema:affiliation N6c792b592f8b4c3a9f91c02228903e75
162 schema:familyName Tuttle
163 schema:givenName Richard
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716677131.78
165 rdf:type schema:Person
166 sg:person.0762066407.91 schema:affiliation N506397512d4b4679991c128f27a561fd
167 schema:familyName Hohneker
168 schema:givenName John A.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762066407.91
170 rdf:type schema:Person
171 sg:pub.10.1007/bf00194543 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041178803
172 https://doi.org/10.1007/bf00194543
173 rdf:type schema:CreativeWork
174 https://app.dimensions.ai/details/publication/pub.1078552732 schema:CreativeWork
175 https://app.dimensions.ai/details/publication/pub.1079722375 schema:CreativeWork
176 https://doi.org/10.1097/00001813-199108000-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044752701
177 rdf:type schema:CreativeWork
178 https://www.grid.ac/institutes/grid.412639.b schema:alternateName UW Carbone Cancer Center
179 schema:name University of Wisconsin Clinical Cancer Center, 53792, Madison, Wisconsin, USA
180 rdf:type schema:Organization
181 https://www.grid.ac/institutes/grid.417123.2 schema:alternateName William S. Middleton Memorial Veterans Hospital
182 schema:name University of Wisconsin Clinical Cancer Center, 53792, Madison, Wisconsin, USA
183 William S. Middleton Memorial Veterans Administration Hospital, 53705, Madison, Wisconsin, USA
184 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...